FOLH1 and prostate cancer: Due to the overexpression of prostate-specific membrane antigen (PSMA) in prostate cancer [139], β-emitting labeled ligands such as 177Lu-PSMA-617, 177Lu-PSMA I&T, 177Lu-PSMA-D4, 177Lu-PSMA-R2, 64/67Cu-RPS-085, and 161Tb-PSMA-617 have been developed, with 177Lu-PSMA-617 and 177Lu-PSMA I&T showing the most promise [140,141,142,143].